Advertisement
CAPVAXIVE (V116) is specifically designed for adults and covers serotypes responsible for approximately 84% of invasive pneumococcal disease in adults 50 years of age and older Across four Phase 3 studies, CAPVAXIVE demonstrated robust immune responses in both vaccine-naïve and vaccine-experienced adult populations Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for: Active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B in individuals 18 years of age and older; Active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B in individuals 18 years of age and📍 Venue: Showbox at The Market
🏠 Address: 1426 1st Ave
🗺️ Extended Address: Seattle, WA 98101
🌆 City: Seattle
📍 Location: 47.6086, -122.339Error occurred: DateTime::__construct(): Failed to parse time string (Showbox at The Market) at position 0 (S): The timezone could not be found in the database
Advertisement
Event Venue & Nearby Stays
Showbox at The Market, 1426 1st Ave, Seattle, WA 98101, US, United States
Tickets
